Effect of physical activity on menopausal symptoms

Effect of physical activity on menopausal symptoms: a randomised clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN54690027

Enrollment

200

Registered

2008-12-17

Start date

2009-01-11

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menopausal symptoms Urological and Genital Diseases Menopausal and other perimenopausal disorders

Interventions

Intervention: Moderate intensity aerobic training for 6 months, 4 times per week walking (or Nordic walking) for 50 minutes at 60% of maximal oxygen uptake (VO2max). Control: Continue earlier habit

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Symptomatic (severe or very severe or moderate daily hot flushes) women 2. Aged 40 - 60 years 3. No current use of oestrogen hormone treatment (HT, without or with progesterone) or any other treatment or withdrawal (wash-out period 3 months) 4. Sedentary (physical exercise less than twice weekly) 5. Six to 36 months from last menstruation (peri-menopausal) 6. Follicle stimulating hormone (FSH) elevated (at least 30 IU/l)

Exclusion criteria

Exclusion criteria: 1. Physically active women (greater than two times/week, at least 30 minutes) 2. Body mass index (BMI) greater than 35 kg/m^2 3. Coronary heart disease, orthopaedic or other diseases preventing from exercising

Design outcomes

Primary

Measure	Time frame
Vasomotor symptoms as measured with validated scale (Women's Health Questionnaire [WHQ]). WHQ enables assessment of depression, anxiety, sleep problems, somatic symptoms with optional subscales for menstrual problems and sexual difficulties. Timepoint of the measurements is 0 and 6 months; baseline and end of the trial in both primary and secondary outcomes.	—

Secondary

Measure	Time frame
1. Other menopausal symptoms, such as urogenital and cognitive symptoms 2. Physical activity and health-related physical fitness (estimated maximal oxygen consumption, muscle strength) 3. Components of metabolic syndrome (weight, waist circumference, and fasting plasma high density lipoprotein [HDL] cholesterol, triglycerides, glucose and insulin) 4. Workability Timepoint of the measurements is 0 and 6 months; baseline and end of the trial in both primary and secondary outcomes.	—

Measure

Time frame

1. Other menopausal symptoms, such as urogenital and cognitive symptoms 2. Physical activity and health-related physical fitness (estimated maximal oxygen consumption, muscle strength) 3. Components of metabolic syndrome (weight, waist circumference, and fasting plasma high density lipoprotein [HDL] cholesterol, triglycerides, glucose and insulin) 4. Workability Timepoint of the measurements is 0 and 6 months; baseline and end of the trial in both primary and secondary outcomes.

—

Countries

Finland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 4, 2026